Adams K, Allen J A, Brooker P C, Henderson L, Jones E, Proudlock R J, Mailland F, Coppi G
Department of Mutagenesis and Cell Biology, Huntingdon Research Centre Ltd., England.
Arzneimittelforschung. 1994 Dec;44(12A):1454-9.
The mutagenic potential of pidotimod ((R)-3-[(S)-(5-oxo-2- pyrrolidinyl)carbonyl]-thiazolidine-4-carboxylic acid, PGT/1A, CAS 121808-62-6) was assessed in a series of five assays designed to measure gene mutation, chromosomal damage and primary DNA damage. All tests were carried out in accordance with appropriate EEC and OECD Guidelines. No indications of mutagenic potential were observed in any of the assays.
匹多莫德((R)-3-[(S)-(5-氧代-2-吡咯烷基)羰基]-噻唑烷-4-羧酸,PGT/1A,CAS 121808-62-6)的致突变潜力在一系列五项旨在检测基因突变、染色体损伤和原发性DNA损伤的试验中进行了评估。所有试验均按照欧洲经济共同体(EEC)和经济合作与发展组织(OECD)的相关指南进行。在任何一项试验中均未观察到致突变潜力的迹象。